Furyl-substituted purines, oxazolopyrimidines and pteridines as adenosine antagonists
申请人:ZENECA LIMITED
公开号:EP0544445A2
公开(公告)日:1993-06-02
Compounds of formula I, and pharmaceutically acceptable salts thereof,
in which R1 is hydrogen (1-6C)alkyl or (1-4C)alkanoyl ;
A is -N=CQ-O-, N=CQ-NR8-, -N=CQ-CH=Nor -N=CH-CQ=N- ;
Q is 2-furyl ;
R8 is hydrogen or C1-4C)alkyl ;
and R2 has any of the meanings given in the specification, processes for preparing the compounds and pharmaceutical compositions containing them. The compounds are useful as adenosine antagonists.
式 I 的化合物及其药学上可接受的盐类、
其中 R1 是氢(1-6C)烷基或(1-4C)烷酰基;
A 是-N=CQ-O-、N=CQ-NR8-、-N=CQ-CH=Nor -N=CH-CQ=N- ;
Q 是 2-呋喃基;
R8 是氢或 C1-4C)烷基;
R2具有说明书、化合物制备工艺和含有这些化合物的药物组合物中给出的任一含义。这些化合物可用作腺苷拮抗剂。
US5300509A
申请人:——
公开号:US5300509A
公开(公告)日:1994-04-05
US5500428A
申请人:——
公开号:US5500428A
公开(公告)日:1996-03-19
2-furyl-oxazolo[5,4-d]-pyrimidines
申请人:Imperial Chemical Industries PLC
公开号:US05300509A1
公开(公告)日:1994-04-05
Compounds of formula I, and pharmaceutically acceptable salts thereof, ##STR1## in which R1 is hydrogen (1-6C)alkyl or (1-4C)alkanoyl; A is --N.dbd.CQ--O--, N.dbd.CQ--NR.sup.8 --, --N.dbd.CQ--CH.dbd.N-- or --N.dbd.CH--CQ.dbd.N--; Q is 2-furyl; R.sup.8 is hydrogen or C1-4C)alkyl; and R.sup.2 has any of the meanings given in the specification, processes for preparing the compounds and pharmaceutical compositions containing them. The compounds are useful as adenosine antagonists.
Pharmaceutical compositions comprising azapurinones useful in treating
申请人:May & Baker Limited
公开号:US03987160A1
公开(公告)日:1976-10-19
8-Azapurin-6-ones substituted in the 2-position by an unsubstituted or substituted phenyl or naphthyl group, or by an alkenyl or alkynyl group, a cycloalkyl group, an alkyl group contaning 2 to 10 carbon atoms, or an alkyl group containing 1 to 10 carbon atoms carrying one or more substitutents selected from halogen atoms and hydroxy, cycloalkyl, alkoxy, phenyl and substituted phenyl groups, and pharmaceutically acceptable salts thereof, possess pharmacological properties useful, for example, in the treatment of allergic bronchial asthma.